Leadership

Erez Rozenfeld joined V-Wave in 2013.  He has more than three decades of proven track record in successful initiation and execution of high-return global business development in the field of medical devices.  He has implemented new business models and strategic plans, overseen mergers and acquisitions, and helped medical innovation companies engage new markets, globally.

Rozenfeld served as CEO of V-Wave prior to global expansion.  His prior industry experience includes being Managing Director at Lumenis UK, as well as in key managerial positions for publicly traded companies, including Teva Group and Agis.  He has expertise in managing emerging companies as Senior VP global operations at Aesthera Inc., CEO of RapiX.

Rozenfeld holds an Executive MBA and BA from Bar Ilan University, Israel.

Dr. William Abraham has been affiliated with V-Wave since 2013, initially as Chairman of its Strategic Advisory Board, then as its Chief Medical Officer in 2015, and becoming the full-time CMO in 2019.  He is responsible for coordinating the activities of the Department of Medical Affairs and serves as a key member of the Senior Management team.

Dr. Abraham is Professor of Internal Medicine, Physiology and Cell Biology and a College of Medicine Distinguished Professor at The Ohio State University, where he formerly served as Director of Cardiovascular Medicine for more than 15 years.  He is an internationally renowned clinician, academician, and researcher in heart failure and has been recognized as one of the “Best Doctors in America” for 18 consecutive years.  His research interests include hemodynamic and neurohormonal mechanisms and clinical drug and device trials in heart failure.  He has led studies that established several new therapies as standard of care for heart failure.  Dr. Abraham has participated as a site principal investigator in over 100 multi-center drug and device clinical trials; additionally, he served as national or international principal investigator or on the executive and steering committees of more than 40 multi-center drug and device trials.  He has authored more than 400 full-length peer-reviewed publications.  Dr. Abraham has consulted for dozens of medical device and pharmaceutical companies and has extensive regulatory experience in the cardiorenal drug and cardiocirculatory system devices arenas in the United States and Europe.

Dr. Abraham recently received the 2022 HFSA Pioneer Award, which notes his innovative role in heart failure, and which helps to set the stage for future generations of heart failure providers.

Dr. Abraham received his undergraduate degree from the University of Pittsburgh and then attended Harvard Medical School.  He was Resident and Chief Resident and then a Fellow in Cardiology and Advanced Heart Failure/Transplant Cardiology at the University of Colorado Health Sciences Center.

William Hughes was appointed as V-Wave Chief Financial Officer in late 2020.  Mr. Hughes brings more than 20 years of financial and operational experience in senior executive leadership positions in the medical device industry.  His accomplishments include successfully managing privately and publicly held enterprises and offering expertise in scaling companies globally, managing operations and finance, and successfully completing fundraising and M&A transactions.

Hughes served as COO and CFO for southern California-based Microvention since 2002, successfully guiding that company through M&A with Terumo Corporation.  Before that he held executive positions at Endocare, Inc., Filenet Corporation as was a Partner at KPMG Peat Marwick.

He has an undergraduate degree in Economics from California Polytechnic State University.

Matt Borenzweig joined V-Wave in June 2019, bringing with him three decades of experience in sales, marketing and clinical trial execution in the cardiovascular arena. He has held leadership positions at Boston Scientific, Arterial Vascular Engineering (AVE), Medtronic, CardioMEMS, Edwards Lifesciences and Abbott.  At Abbott, he held the position of Division VP of Structural Heart where he managed all commercial aspects of the Abbott’s product portfolio in the United States.

Borenzweig has been involved with many groundbreaking product launches including aortic and mitral valvuloplasty, temperature sensing RF ablation, novel coronary and peripheral stents, AAA stent grafts, implantable sensors for remote heart failure pressure monitoring, novel heart valves and valve repair, next generation MitraClip TMVr, PFO, PDA, and septal occluders.

He has an undergraduate degree in Biological Sciences from the University of Southern California.

Lior Rosen joined V-Wave in 2014 and has been instrumental in developing and scaling up its technology, clinical programs, and operations. He brings more than 20 years of executive managerial experience in medical device development from concept through commercialization with focus on cardiovascular products. Prior to joining V-Wave, Rosen served as VP R&D and Co-CEO at CorAssist Cardiovascular.  Rosen holds a B.Sc. in Mechanical Engineering from the Technion and M.Sc. in Biomedical Engineering from Tel Aviv University.

Dudy Stolick’s 30-year career covers multiple finance leadership positions in life science and electronics industries.  He has previously held CFO roles at Exalenz Bioscience Ltd., and Brainstorm Cell Therapeutics, and has served a corporate controller for M-Systems.  Stolick holds a BA degree in Economy and Accounting from Ben Gurion University.

Lydia Telep has a distinguished career in the medical device regulatory field spanning over 30 years.  Before joining V-Wave, she was the VP of Regulatory Affairs for Second Sight Medical Products and a Director of Regulatory Affairs at Abbott / St. Jude Medical.  Telep holds a MS in Bioengineering from California State University, Northridge (CSUN) and did her undergraduate studies at UCLA.

Gali Tzury has over twenty years of medical technology experience across quality and regulatory matters.  Previously she has served as Vice President, QA/RA/CA at Rapid Medical and as a QA Manager at Alma Lasers.  She holds a BA from Bar Ilan University and a CQE from Technion Institute of Technology.

Werner Hafelfinger has a career that spans four decades across both the medtech and aerospace industries.  Before joining V-Wave he served as VP of Operations, Manufacturing, and R&D at St. Jude Medical.  Prior to that role, he was VP of Operations at Savacor, Inc.  Hafelfinger had originally started his career in the aerospace industry, including a leadership position as COO / Vice President of Operations at Pacific Aerospace & Electronics.  He holds a MS degree from Columbia University in Mechanical Engineering.

Debbie Deutsch joined V-Wave in 2020, bringing over 20 years of cardiovascular experience in the medical device industry, where she has been involved in clinical trials for multiple groundbreaking products, including drug eluting coronary stents, TAVR, and mitral and tricuspid valve replacement and repair. Before joining V-Wave, she was Sr. Director of Clinical Safety at Edwards Lifesciences, following increasing roles of responsibility in quality and clinical affairs, and where she also supported several company acquisitions. Previously she held roles in quality at Cordis and OrbusNeich. Deutsch holds a Bachelor of Science in Nursing from the University of Pennsylvania and worked as a cardiac and cath lab nurse for 10 years.